• Home
  • News
  • Coins2Day 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Leadershipmichael cohen

‘Yesterday Was Not a Good Day.’ Novartis CEO Says Hiring Trump Lawyer Michael Cohen Was a Mistake

By
Bloomberg
Bloomberg
Down Arrow Button Icon
By
Bloomberg
Bloomberg
Down Arrow Button Icon
May 11, 2018, 4:07 AM ET

Novartis AG Chief Executive Officer Vas Narasimhan said the Swiss drugmaker “made a mistake” in signing up lawyer Michael Cohen to give the company insight on President Donald Trump’s health-care plans.

“Yesterday was not a good day for Novartis,” Narasimhan wrote to employees Thursday in a letter reviewed by Bloomberg News. A day earlier, the drug company said it had paid $1.2 million to a firm led by Cohen, who is at the center of a U.S. Law enforcement probe, as well as a civil lawsuit related to payments to an exotic dancer.

“We made a mistake in entering into this engagement and, as a consequence are being criticized by a world that expects more from us,” Narasimhan said in the letter. “What defines us now is how we respond to this difficult situation.”

Novartis hired Cohen’s company in 2017. The company said it quickly determined that the lawyer’s firm would be unable to provide the services it anticipated and decided not to engage further, but was contractually bound to keep making monthly payments of $100,000.

While Novartis said it got little from Cohen, the arrangement dragged Novartis (NVS) into Special Counsel Robert Mueller’s probe into suspected Russian meddling in the U.S. Presidential election. The company said it was contacted by Mueller’s office in November, though now considers its role in that inquiry closed.

The latest developments come just as the company seeks to move beyond a string of legal troubles and its new CEO looks to reshape the company’s culture and reputation. Separately, AT&T (T) paid Cohen up to $600,000 for insights and asked him to look into its proposed $85 billion merger with Time Warner (TWX) as it sought government antitrust approval, according to a person familiar with the matter.

Novartis shares fell 0.5% in early trading in Zurich, having dropped 6% this year.

Narasimhan, a 13-year company veteran, took the helm earlier this year, replacing Joe Jimenez. He said in his letter that he went to sleep “frustrated and tired” and woke up “full of determination.”

“I look to you to remain resilient and keep your focus on serving patients,” he said.

About the Author
By Bloomberg
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Coins2Day
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.